Captor Capital Corp. (CSE:CPTR, FRANKFURT:NMV, STUTTGART:NMVA, USOTC:CPTRF), (“Captor” or the “Company”) (CSE: CPTR) is pleased to announce that the Ontario Securities Commission has granted a full revocation of the cease trade order previously issued against the Company (the “CTO”). The CTO was issued as a result of the Company’s failure to file its audited financial statements for the year ended March 31, 2019 and related Management Discussion and Analysis. The Company is also pleased to announce that the trading of its shares on the Canadian Securities Exchange has been reinstated and trading will commence on November 7, 2019.

On November 4, 2019, the Company filed its audited financial statements for the fiscal period ended March 31, 2019 and unaudited interim financial statements for the three months ended June 30, 2019, respectively, including management’s discussion and analysis for such periods and accompanying certificates of the Chief Executive Officer and Chief Financial Officer, as required under applicable securities laws.


ADDITIONAL INFORMATION
Additional information relating to the Company is available on SEDAR at www.sedar.com.

About Captor Capital Corp.

Captor Capital Corp. is a Canadian vertically integrated cannabis company listed on the Canadian Securities Exchange, the OTC, and the Frankfurt and Stuttgart stock exchanges. Captor provides recreational and medical marijuana-based products to consumers and also owns and operates advanced growing facilities, which produce consistent high-quality contaminant free marijuana for its customers, as well as other high demand cannabis-based goods for consumption. The Company follows a strategy of acquiring cash flowing established companies and organizations with growth potential that require capital to scale. Captor currently has a number of revenue generating cannabis assets including the CHAI Cannabis Co. dispensaries in Santa Cruz and Monterey, CA. The Company also owns Mellow Extracts, a highly regarded producer of cannabis extracts based in Costa Mesa, CA.

Click here to connect with Captor Capital Corp. (CSE:CPTR, FRANKFURT:NMV, STUTTGART:NMVA, USOTC:CPTRF) for an Investor Presentation.

Source

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Keep reading... Show less

THC-O-Acetate to be Produced Through Company’s Specialty Molecule Division

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), an extraction company that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The division is supported by the Company’s existing intellectual property (“IP”) portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate.

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (the “Company”) is pleased to announce that it has completed construction of an industrial-grade distribution site and launched third party distribution services.

As part of its Phase 1 Construction project at the 196,000 square foot facility, the Company has built out 16,000 square feet of retail-ready product storage space, installed automated, assembly-line style packaging equipment for jar and pouch production, and built out a climate-controlled area that can store 30 tractor-trailer loads of cannabis and 230 pallets positions of -40 degree Fahrenheit freezers for storing live resin and live resin products. A secure loading bay and a small in-house fleet of refrigerated trucks is also in place.

Keep reading... Show less

Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“GWS” or the “Company”) is pleased to provide the following corporate update highlights on two portfolio clients KaleidoMyco LLC and Biominerales Pharma Corp. and announces the signing of the one-stop digital marketing team of North Equities Corp.

“With the talent, skills and resources we have at Global Wellness, we are well positioned to develop leading nutraceutical product portfolio brands focused on health and well-being. As hemp-extract and psilocybin is legalized in more jurisdictions such as Oregon where we already have a strong strategic relationship, we can then easily extend our existing product range, which will already have established routes to market and brand recognition, to include myco-dosing products. KaleidoMyco products will be in stores and on a consumer digital platform in the USA shortly and is currently being consumer tested in Europe as well. Our shareholders and customers are extremely important to us and we look forward to meeting the milestones we have outlined with the help of North Equities,” said Meris Kott, CEO.

Keep reading... Show less

VINIA(R)’s ability to increase dilation of arteries and to reduce blood vessel constriction allows it to fight the human aging process

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) announces that its flagship VINIA® product is the only dietary supplement available in the US market which has the capability for both reducing the endothelin 1 (ET1) enzyme as well as increasing the nitric oxide (NO) molecules, in order to increase the dilation of arteries and thereby improve blood flow. The presence of ET1 constricts the blood vessel, whereas the presence of NO dilates it. As a result of its “double-action” effect (proven by the Flow Mediated Dilatation (FMD) measurements in a double-blinded Placebo-controlled clinical trial*and in an in-vitro study** whose results were both published), VINIA® is uniquely positioned to combat the aging process caused by a reduction in blood flow.

Keep reading... Show less